Activase manufacturing "interval"
Executive Summary
Genentech is "maintaining adequate stocks of TPA to meet current demand and to respond to renewed growth in the market for thrombolytic, or clot-dissolving, therapy," the firm said in an Oct. 13 statement explaining its decision to halt production of the drug for the balance of 1988. Genentech said it manufacturers TPA "on a campaign basis" with "intervals scheduled between the manufacture of different products." Genentech's manufacturing plant during the first half of 1988 ran "at a rate considerably higher than matching sales" in order to allow the plant to be available for production of other cell-based products, including the CD4 potential AIDS therapy, the firm maintained. CD4 entered Phase I study in August.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.